Point72 Asset Management L.P. Purchases New Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Point72 Asset Management L.P. acquired a new stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 99,800 shares of the company's stock, valued at approximately $980,000. Point72 Asset Management L.P. owned about 0.17% of Ginkgo Bioworks at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. OMERS ADMINISTRATION Corp acquired a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at approximately $342,000. Millennium Management LLC boosted its position in shares of Ginkgo Bioworks by 357.4% during the 4th quarter. Millennium Management LLC now owns 670,065 shares of the company's stock valued at $6,580,000 after purchasing an additional 523,571 shares in the last quarter. Coastal Bridge Advisors LLC raised its stake in Ginkgo Bioworks by 1,609.8% during the 4th quarter. Coastal Bridge Advisors LLC now owns 276,817 shares of the company's stock worth $2,718,000 after buying an additional 260,627 shares during the period. Balyasny Asset Management L.P. raised its stake in Ginkgo Bioworks by 277.1% during the 4th quarter. Balyasny Asset Management L.P. now owns 80,743 shares of the company's stock worth $793,000 after buying an additional 59,334 shares during the period. Finally, Bank of America Corp DE raised its stake in Ginkgo Bioworks by 780.6% during the 4th quarter. Bank of America Corp DE now owns 3,764,455 shares of the company's stock worth $36,967,000 after buying an additional 3,336,964 shares during the period. Institutional investors and hedge funds own 78.63% of the company's stock.

Ginkgo Bioworks Stock Performance

Shares of Ginkgo Bioworks stock traded down $0.03 on Tuesday, hitting $6.96. The company had a trading volume of 287,971 shares, compared to its average volume of 1,455,528. The stock has a market capitalization of $407.50 million, a price-to-earnings ratio of -0.53 and a beta of 1.29. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $5.00 and a 1 year high of $27.16. The stock has a 50 day moving average of $7.20 and a 200-day moving average of $9.05.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.35). The company had revenue of $48.32 million during the quarter, compared to analysts' expectations of $38.70 million. Ginkgo Bioworks had a negative return on equity of 58.54% and a negative net margin of 298.78%. Equities analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.